The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Pan-RAS and adenosine pathway inhibitors for pancreatic cancer
Davide Melisi, MD, PhD, University of Verona, Verona, Italy, discusses the progress of novel agents for pancreatic cancer, focusing on pan-RAS inhibitors and adenosine pathway inhibitors. These developments signal promising new therapeutic options for improving patient outcomes in this challenging disease. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
